JohnFGerecitanoMD

Oncology • New York, NY

Hematologic Oncology

Assistant Professor, Medicine, Weill Cornell Medical College

Join to view full profile

Dr. Gerecitano is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gerecitano's full profile

Already have an account?

Office
1275 York Ave
New York, NY 10021
Phone+1 646-227-3813

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Pennsylvania Health SystemResidency, Internal Medicine, 2000 - 2003
New York University School of MedicineClass of 2000

Certifications & Licensure

NJ State Medical License 2006 - 2025
NY State Medical License 2003 - 2018
PA State Medical License 2001 - 2003

Clinical Trials

Bortezomib in Treating Patients With Lymphoproliferative Disorders Start of enrollment: 2001 Jun 01
Completed
Phase 2
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2005 Dec 13
Completed
Phase 1, Phase 2
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Start of enrollment: 2010 Aug 27
Completed
Phase 1, Phase 2
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2011 May 01
Completed
Phase 2
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Start of enrollment: 2011 Jul 01
Completed
Phase 1, Phase 2
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies Start of enrollment: 2011 Jul 06
Completed
Phase 1
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma Start of enrollment: 2013 Dec 05
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Zachary D Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron
Haematologica. 2024-08-01
1 citations
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Zachary D Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron
Haematologica. 2024-04-01
Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design.
Anita Kumar, Carla Casulo, Erel Joffe, Craig Moskowitz, John Gerecitano
Leukemia & Lymphoma. 2022-12-01

Press Mentions

EZH2 Inhibitor Tested as Epigentic Option in NHL TypesOctober 26th, 2017
Two Late-Stage Trials Test Novel PI3K Inhibitor in Non-Hodgkin LymphomaJune 16th, 2017
$LBA-2 Venetoclax plus Rituximab Is Superior to Bendamustine plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study$
LBA-2 Venetoclax plus Rituximab Is Superior to Bendamustine plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano StudyDecember 2nd, 2017

Professional Memberships

American Society of Clinical Oncology - ASCO
Member